Alx Oncology Earnings Call Highlights Biomarker Momentum

Alx Oncology Holdings, Inc. ((ALXO)) has held its Q4 earnings call. Read on for the main highlights of the call.

Alx Oncology struck an upbeat tone on its latest earnings call, highlighting strengthening clinical validation for lead asset evorpocept and steady progress with its ALX 2004 antibody‑drug conjugate. Management balanced this optimism with candid discussion of early dataset sizes, biomarker and regulatory uncertainties, and the need to navigate long timelines before key value‑defining readouts.

CD47 biomarker delivers robust, cross‑tumor validation

Multiple independent datasets underscored CD47 as a predictive biomarker for evorpocept across solid tumors. In HER2‑positive gastric cancer, CD47‑high patients saw a 65% response rate versus 26% on control, with progression‑free survival of 18.4 months versus 7.0 and more than tripled duration of response, while a small HER2‑positive breast cohort showed a 56% response rate concentrated in CD47‑overexpressing tumors.

Compelling activity in indolent non‑Hodgkin’s lymphoma

In first‑line indolent non‑Hodgkin’s lymphoma, evorpocept combined with R‑squared delivered a 92% complete response rate, which management characterized as nearly double historical R‑squared alone. The company framed these data as evidence that evorpocept can broadly enhance Fc‑active antibodies in hematologic cancers, potentially opening multiple development avenues if larger studies confirm durability and safety.

ALX 2004 EGFR ADC advancing through dose escalation

ALX 2004, the company’s EGFR‑targeting ADC, has cleared its first two dose cohorts and is now dosing at 4 mg/kg in phase 1 dose escalation with planned expansion. Preclinical work showed strong, dose‑dependent antitumor activity across EGFR levels and mutations without EGFR‑related skin or lung toxicity in primates, with full dose‑escalation safety data expected in the second half of 2026.

Financing extends cash runway into 2028

Alx Oncology significantly strengthened its balance sheet with a $150 million equity raise, yielding $140.4 million in net proceeds on top of $48.3 million in year‑end cash and investments. Management said the enlarged cash position should fund operations through 2028, giving the company room to run multiple clinical programs and reach several important data catalysts without near‑term capital pressure.

Sharpened operational focus on two lead programs

The company stressed a tight operational focus on evorpocept and ALX 2004 as its core value drivers, trimming earlier research to conserve capital. Near‑term priorities include delivering full biomarker analysis from the danitatumab plus evorpocept study at ESMO Breast 2026, completing ALX 2004 dose escalation, and progressing the ASPEN phase 2 breast trial toward top‑line data.

Improved cost discipline narrows quarterly net loss

Alx Oncology reported a quarterly GAAP net loss of $22.8 million, or $0.42 per share, improving from $29.2 million, or $0.55 per share, a year earlier. Management attributed the roughly 22% reduction in dollar losses and 24% per‑share decline to lower stock‑based compensation, streamlined personnel costs, and reduced preclinical spending after pipeline reprioritization.

ASPEN‑9 trial expanded and biomarker strategy refined

The phase 2 ASPEN‑9 breast study was upsized from 80 to as many as 120 patients, with the primary endpoint reset to response rate in CD47‑high patients to power biomarker cut‑point selection. Despite the expansion, Alx Oncology maintained guidance for top‑line data on the first 80 patients by mid‑2027, aiming to refine CD47 as a companion diagnostic in the post‑in‑HER2 setting.

Small cohorts highlight promise but keep risk elevated

Management acknowledged that several supportive datasets, including the late‑line HER2 breast cohort with only nine confirmed HER2‑positive patients, remain small and exploratory. While the signals are encouraging, investors were reminded that larger, controlled studies will be needed to validate efficacy magnitude, confirm biomarker performance, and underpin future regulatory discussions.

Uncertainty around CD47 prevalence and cutoff

The company noted meaningful uncertainty regarding the optimal CD47 immunohistochemistry cutoff and true biomarker prevalence in post‑in‑HER2 breast cancer, which drove the ASPEN upsizing. Literature suggests roughly 40–57% of patients could be CD47‑high, but the exact threshold must be established prospectively, a factor that could ultimately shape trial outcomes and regulatory strategy.

Extended timelines before major clinical catalysts

Investors will need patience, as key clinical milestones are spaced over the next 12–18 months and beyond, with full ALX 2004 dose‑escalation data not expected until the second half of 2026. The pivotal ASPEN top‑line readout for 80 breast cancer patients is targeted for mid‑2027, underscoring that while the pipeline is advancing, significant value‑defining efficacy data remain some distance away.

Managing ADC class safety risks with ALX 2004

Although ALX 2004’s nonhuman primate studies did not reveal interstitial lung disease or notable skin toxicity, management stressed ongoing vigilance given class risks of topoisomerase I‑based ADCs. The true therapeutic window and tolerability profile will only be established in humans over time, making the phase 1 dose‑escalation outcomes critical for the asset’s future.

Dependence on capital markets and lack of revenue

The company conceded that, prior to the recent financing, its $48.3 million cash balance made the capital raise essential to maintain operations. With continued quarterly GAAP losses and no commercial revenue, Alx Oncology remains reliant on accessing capital markets until its programs reach de‑risking milestones and potential partnering or commercialization opportunities.

Navigating a shifting post‑in‑HER2 regulatory landscape

Evolving treatment options following in‑HER2 approval introduce uncertainty around therapy sequencing, trial enrollment, and comparator benchmarks in breast cancer. Alx Oncology is working on a companion diagnostic strategy for CD47, but the final regulatory pathway remains fluid as standards of care shift and agencies weigh biomarker‑driven trial designs.

Guidance underscores multi‑year clinical and financial runway

Management reiterated that year‑end cash of $48.3 million plus $140.4 million in net equity proceeds should support operations through 2028, even as the company continues to post GAAP losses. Key upcoming milestones include detailed biomarker data from the danitatumab combination at ESMO Breast 2026, ALX 2004 dose‑escalation readout in the second half of 2026, and ASPEN’s 80‑patient top‑line breast data in mid‑2027, with a goal of having both programs pivotal‑ready by late 2026.

Alx Oncology’s earnings call painted a picture of a company with increasingly convincing clinical biology, a reinforced balance sheet, and a focused development plan, albeit with material execution and timing risks. For investors, the story now hinges on whether emerging CD47‑driven signals and the ALX 2004 ADC can translate into durable, larger‑scale efficacy as the long‑dated clinical catalysts begin to unfold.